Literature DB >> 8544465

Rates of growth of human neoplasms: Part II.

J S Spratt1, J S Meyer, J A Spratt.   

Abstract

Part I of this study [Spratt JS, Meyer JS, Spratt JA: J Surg Oncol 60:137-146, 1995] reviewed the early reports of investigators, predominantly mathematical biologists and statisticians considering the mathematical laws that would describe the growth of a neoplasm. Included were cytokinetic measurements of the mitotic index, thymidine labeling index, bromodeoxy-uridine labeling index, and the relation of these indices to the potential tumor volume doubling time. The actual doubling time of benign and malignant colonic neoplasms were reported. This second part provides the cumulative observations on the actual doubling times of pulmonary metastases, primary pulmonary cancers, skeletal sarcomas, melanomas, a chemodectoma, tumors of maxillary antrum, testicular cancers, prostate cancer, and the relation between the accumulation of multiple primary cancers and growth rates. The most complete data set is for breast cancer concluding that the cancer growth curve is a decelerating curve with great natural variance. Understanding of the rates of growth of human cancers is essential for understanding the spectrum of cancer behavior observed clinically.

Entities:  

Mesh:

Year:  1996        PMID: 8544465     DOI: 10.1002/1096-9098(199601)61:1<68::aid-jso2930610102>3.0.co;2-e

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  29 in total

1.  Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells.

Authors:  Lyn M Huff; Dan L Sackett; Marianne S Poruchynsky; Tito Fojo
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

2.  Treatment of hepatic metastases from colorectal carcinoma.

Authors:  J S Spratt
Journal:  J Gastrointest Surg       Date:  1998 May-Jun       Impact factor: 3.452

Review 3.  Angiogenesis, metastasis, and endogenous inhibition.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma.

Authors:  Agostino Maria De Rose; Alessandro Cucchetti; Gennaro Clemente; Francesco Ardito; Ivo Giovannini; Giorgio Ercolani; Felice Giuliante; Antonio Daniele Pinna; Gennaro Nuzzo
Journal:  J Gastrointest Surg       Date:  2013-01-05       Impact factor: 3.452

Review 5.  Moderate alcohol consumption and breast cancer in women: from epidemiology to mechanisms and interventions.

Authors:  Philip J Brooks; Samir Zakhari
Journal:  Alcohol Clin Exp Res       Date:  2012-10-16       Impact factor: 3.455

6.  Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.

Authors:  Deborah Grady; Jane A Cauley; Mary Jane Geiger; Marcel Kornitzer; Lori Mosca; Peter Collins; Nanette K Wenger; Jingli Song; John Mershon; Elizabeth Barrett-Connor
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

Review 7.  Cancer progression and the invisible phase of metastatic colonization.

Authors:  Christoph A Klein
Journal:  Nat Rev Cancer       Date:  2020-10-06       Impact factor: 60.716

8.  Occult breast tumor reservoir: biological properties and clinical significance.

Authors:  Richard J Santen; Wei Yue; Daniel F Heitjan
Journal:  Horm Cancer       Date:  2013-04-30       Impact factor: 3.869

9.  Timeline metastatic progression: in the wake of the « seed and soil » theory.

Authors:  Aymeric Amelot; Louis-Marie Terrier; Jean-Jacques Mazeron; Charles-Ambroise Valery; Philippe Cornu; Alexandre Carpentier; Marc Leveque
Journal:  Med Oncol       Date:  2017-10-06       Impact factor: 3.064

10.  Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.

Authors:  Richard J Santen; Wei Yue; Daniel F Heitjan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-14       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.